EDAP to Announce Second Quarter 2024 Financial Results on August 28, 2024
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, has announced it will release its financial results for the second quarter ended June 30, 2024, before markets open on Wednesday, August 28th, 2024. The company will host a conference call and webcast on the same day at 8:30am EDT.
The call will be conducted by Ryan Rhodes (CEO), Ken Mobeck (CFO), and François Dietsch (Chief Accounting Officer). Investors can join the call using the provided domestic and international dial-in numbers or through the webcast link.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EDAP gained 0.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to host conference call and webcast on Wednesday, August 28th at 8:30am EDT
LYON, France, August 7, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2024, before the markets open on Wednesday, August 28th, 2024.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
| Date: | Wednesday, August 28th |
| Time: | 8:30 am EDT |
| Domestic: | 1-877-300-8521 |
| International: | 1-412-317-6026 |
| Passcode: | 10190872 |
| CallMeTM | LINK (active 15 minutes prior to conference call) |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1679882&tp_key=f499a45540 |
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
When will EDAP TMS SA release its Q2 2024 financial results?
What time is EDAP's Q2 2024 earnings conference call scheduled for?
Who will be conducting EDAP's Q2 2024 earnings call?
What is the domestic dial-in number for EDAP's Q2 2024 earnings call?
